•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Velocity Financial, Inc. (VEL) Q1 2026 Earnings Call Transcript
Velocity Financial, Inc. Reports First Quarter 2026 Results
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
Velocity Financial, Inc. Announces Date of First Quarter 2026 Financial Results Webcast and Conference Call
Velocity Financial, Inc. (VEL) Q4 2025 Earnings Call Transcript
Velocity Financial, Inc. Reports Fourth Quarter and Full-Year 2025 Results
Velocity Financial, Inc. Announces Closing of Offering of $500 Million of Senior Notes Due 2031
Velocity Financial, Inc. Announces Date of Fourth Quarter and Full Year 2025 Financial Results Webcast and Conference Call
Velocity Financial, Inc. Announces Pricing of $500 Million of Senior Notes Due 2031
Velocity Financial, Inc. Announces Proposed Offering of $500 Million of Senior Notes Due 2031
Velocity Financial, Inc. Announces Preliminary Expected Fourth Quarter and Full-Year 2025 Results
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
Velocity Financial, Inc. Announces Nonperforming Loan Sale and New Servicing Partnership
Velocity Financial, Inc. (VEL) Q3 2025 Earnings Call Transcript
Velocity Financial, Inc. Reports Third Quarter 2025 Results
Velocity Financial, Inc. Announces Date of Third Quarter 2025 Financial Results Webcast and Conference Call
Velocity Financial, Inc. Announces Dual Listing on NYSE Texas
Velocity Financial, Inc. (VEL) Q2 2025 Earnings Call Transcript
Velocity Financial, Inc. Announces Date of Second Quarter 2025 Financial Results Webcast and Conference Call
Velocity Commercial Capital Securitization Ratings Affirmed and Upgraded by Kroll Bond Rating Agency